(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 September 2020 (17.09.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/186207 A8

(51) International Patent Classification:
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2020/022738

(22) International Filing Date:
13 March 2020 (13.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/817,904	13 March 2019 (13.03.2019)	US
62/856,432	03 June 2019 (03.06.2019)	US

(71) Applicant: **GENERATION BIO CO.** [US/US]; 301 Binney Street, 4th Floor, Cambridge, MA 02142 (US).

(72) Inventors: **KERR, Douglas, Anthony**; c/o Generation Bio Co., 301 Binney Street, 4th Floor, Cambridge, MA 02142 (US). **KLATTE, Debra**; c/o Generation Bio Co., 301 Binney Street, 4th Floor, Cambridge, MA 02142 (US). **SAMAYOA, Phillip**; c/o Generation Bio Co., 301 Binney Street, 4th Floor, Cambridge, MA 02142 (US). **SILVER, Nathaniel**; c/o Generation Bio Co., 301 Binney Street, 4th Floor, Cambridge, MA 02142 (US).

(74) Agent: **CLARKE, Marcie, B.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
12 November 2020 (12.11.2020)

(15) Information about Correction:
see Notice of 12 November 2020 (12.11.2020)

WO 2020/186207 A8

(54) Title: NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FVIII THERAPEUTICS

(57) Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FVIII protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FVIII protein *in vitro*, *ex vivo* and *in vivo* using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of FVIII protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FVIII protein. Such FVIII protein can be expressed for treating disease, *e.g.*, hemophilia A.